Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SPN052
MIFTS: 54

Spondyloarthropathy

Categories: Bone diseases, Eye diseases, Genetic diseases, Immune diseases, Muscle diseases, Rare diseases, Respiratory diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Spondyloarthropathy

About this section

MalaCards integrated aliases for Spondyloarthropathy:

Name: Spondyloarthropathy 12 15 39 17
Spondylarthropathies 44 70
Spondyloarthropathy, Susceptibility to 29
Spondarthropathy 12
Spondylarthrosis 12
Spondylarthritis 70

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Bone diseases Immune diseases Eye diseases Respiratory diseases Muscle diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:1123
MeSH 44 D025242
SNOMED-CT 67 8847002
UMLS 70 C0949690 C0949691
Sources

Summaries for Spondyloarthropathy

About this section
MalaCards based summary : Spondyloarthropathy, also known as spondylarthropathies, is related to juvenile spondyloarthropathy and spondyloarthropathy 1, and has symptoms including sciatica An important gene associated with Spondyloarthropathy is SPDA2 (Spondyloarthropathy, Susceptibility To, 2), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Tofacitinib and Pamidronate have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and skin, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : 73 Spondyloarthropathy or spondyloarthrosis refers to any joint disease of the vertebral column. As such,... more...

Sources

Related Diseases for Spondyloarthropathy

About this section

Diseases in the Spondyloarthropathy family:

Spondyloarthropathy 1 Spondyloarthropathy 2
Spondyloarthropathy 3 Juvenile Spondyloarthropathy

Diseases related to Spondyloarthropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 807)
# Related Disease Score Top Affiliating Genes
1 juvenile spondyloarthropathy 32.9 LTA IL2
2 spondyloarthropathy 1 32.8 TNFSF11 TNF MMP3 IL6 IL17A HLA-B
3 spondylarthropathy 32.4 TNF HLA-B
4 ankylosis 31.1 TNFSF11 TNF IL17A
5 synovitis 31.0 TNFSF11 TNF MMP3 IL6 IL1B
6 reactive arthritis 30.9 TNF IL6 IL23A IL1B IL17A IL10
7 spondylitis 30.9 TNFSF11 TNF LTA IL6 IL23A IL1B
8 iridocyclitis 30.9 TNF IL6 IL1B IL17A IL10 HLA-B
9 arthropathy 30.8 TNFSF11 TNF MMP3 LTA IL6 IL1B
10 carpal tunnel syndrome 30.8 IL6 IL2 IL1B
11 aortitis 30.7 TNF IL6 IL1B IL17A
12 end stage renal disease 30.7 TNF IL6 IL1B IL10
13 fibromyalgia 30.7 TNF IL6 IL1B IL10
14 familial mediterranean fever 30.7 TNF IL6 IL1B IL17A IL10 HLA-A
15 bursitis 30.7 TNF MMP3 IL6 IL1B
16 crohn's colitis 30.7 TNF IL2 IL1B IFNG
17 brucellosis 30.6 TNF IL6 IL4 IL2 IL17A IL10
18 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.6 IL17A IL10 IFNG
19 vasculitis 30.6 TNF IL6 IL17A HLA-B
20 juvenile arthritis 30.6 IL6 IL10 HLA-A
21 bone resorption disease 30.6 TNFSF11 TNF IL6 IL1B
22 hidradenitis 30.6 TNF LTA IL1B IL17A IFNG
23 hidradenitis suppurativa 30.6 TNF LTA IL1B IL17A IFNG
24 tendinitis 30.5 TNF MMP3 IL6 IL1B
25 temporal arteritis 30.5 TNF IL6 IL2 IL1B IL17A IFNG
26 spinal disease 30.5 TNF IL6 IL1B IL17A
27 dysentery 30.5 TNF IL6 IL1B IL10
28 uveitis 30.5 TNF LTA IL6 IL4 IL2 IL1B
29 fasciitis 30.5 TNF LTA IL6 IL2 IFNG
30 radiculopathy 30.4 IL6 IL17A IL10
31 osteoarthritis 30.4 TNFSF11 TNF MMP3 IL6 IL1B IL17A
32 skeletal tuberculosis 30.4 TNF IFNG
33 mixed connective tissue disease 30.4 TNF IL6 IL10 IFNG
34 urethritis 30.4 TNF IL6 IL1B IL10
35 chlamydia 30.4 TNF IL6 IL4 IL1B IL17A IL10
36 iritis 30.3 TNF IL6 IL17A IL10 HLA-B
37 crohn's disease 30.3 TNF IL6 IL4 IL23A IL2 IL1B
38 proliferative glomerulonephritis 30.3 IL6 IL4 IFNG
39 tenosynovitis 30.3 TNF MMP3 IL6 IL1B
40 enterocolitis 30.3 TNF IL6 IL10
41 herpes zoster 30.3 TNF IL2 IL10 IFNG HLA-B HLA-A
42 nephrotic syndrome 30.3 TNF IL6 IL4 IL2 IL17A
43 ulcerative colitis 30.2 TNF IL6 IL4 IL23A IL2 IL1B
44 osteomyelitis 30.2 TNFSF11 TNF IL6 IL4 IL1B IL10
45 scleritis 30.2 TNF IL4 IFNG
46 cardiogenic shock 30.2 TNF IL6
47 bone inflammation disease 30.2 TNFSF11 TNF MMP3 IL6 IL4 IL2
48 sarcoidosis 1 30.2 TNF LTA IL2 IL1B IFNG HLA-A
49 colitis 30.2 TNF IL6 IL4 IL23A IL2 IL1B
50 systemic scleroderma 30.2 TNF IL6 IL4 IL17A IL10 IFNG

Graphical network of the top 20 diseases related to Spondyloarthropathy:



Diseases related to Spondyloarthropathy
Sources

Symptoms & Phenotypes for Spondyloarthropathy

About this section

UMLS symptoms related to Spondyloarthropathy:


sciatica

GenomeRNAi Phenotypes related to Spondyloarthropathy according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-103 9.72 HLA-A HLA-B HLA-C
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-110 9.72 HLA-A HLA-B HLA-C
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-14 9.72 HLA-C
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-156 9.72 HLA-A HLA-B HLA-C
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-178 9.72 HLA-A HLA-B HLA-C
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-19 9.72 HLA-A HLA-B HLA-C
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-202 9.72 HLA-C
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-31 9.72 HLA-A HLA-B HLA-C
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-7 9.72 HLA-A HLA-B HLA-C
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 9.72 HLA-C
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-95 9.72 HLA-C

MGI Mouse Phenotypes related to Spondyloarthropathy:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.28 HLA-A IFNG IL10 IL17A IL17F IL1B
2 immune system MP:0005387 10.28 HLA-A IFNG IL10 IL17A IL17F IL1B
3 mortality/aging MP:0010768 10.17 HLA-A IFNG IL10 IL17A IL17F IL1B
4 endocrine/exocrine gland MP:0005379 10.16 HLA-A IFNG IL10 IL17A IL2 IL4
5 digestive/alimentary MP:0005381 10.13 IFNG IL10 IL17A IL17F IL2 IL23A
6 craniofacial MP:0005382 10.1 IFNG IL10 IL17A IL17F IL1B IL4
7 integument MP:0010771 10.07 IFNG IL10 IL17A IL1B IL22RA1 IL23A
8 neoplasm MP:0002006 9.86 IFNG IL10 IL1B IL2 IL23A IL6
9 no phenotypic analysis MP:0003012 9.81 HLA-A IFNG IL10 IL17A IL2 IL23A
10 respiratory system MP:0005388 9.65 IFNG IL10 IL17A IL17F IL2 IL4
11 skeleton MP:0005390 9.36 IFNG IL10 IL17A IL17F IL1B IL4
Sources

Drugs & Therapeutics for Spondyloarthropathy

About this section

Drugs for Spondyloarthropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 94)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tofacitinib Approved, Investigational Phase 4 477600-75-2
2
Pamidronate Approved Phase 4 40391-99-9 4674
3
Etoricoxib Approved, Investigational Phase 4 202409-33-4 123619
4
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
5
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
6
Certolizumab pegol Approved Phase 4 428863-50-7
7
Hydroxychloroquine Approved Phase 4 118-42-3 3652
8
Sulfasalazine Approved Phase 4 599-79-1 5359476 5353980
9
Infliximab Approved Phase 4 170277-31-3
10
Etanercept Approved, Investigational Phase 4 185243-69-0
11
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
12
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
13
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
14
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
15
Meloxicam Approved, Vet_approved Phase 4 71125-38-7 5281106 54677470
16 Pharmaceutical Solutions Phase 4
17 Triamcinolone diacetate Phase 4
18 triamcinolone acetonide Phase 4
19 Triamcinolone hexacetonide Phase 4
20 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
21 Anti-Arrhythmia Agents Phase 4
22 Sodium Channel Blockers Phase 4
23 Anesthetics Phase 4
24 Anesthetics, Local Phase 4
25 Diuretics, Potassium Sparing Phase 4
26 Anti-Infective Agents Phase 4
27 Antimalarials Phase 4
28 Antiparasitic Agents Phase 4
29 Antiprotozoal Agents Phase 4
30 Immunoglobulins Phase 4
31 Antibodies Phase 4
32 Analgesics, Non-Narcotic Phase 4
33 Cyclooxygenase 2 Inhibitors Phase 4
34 Analgesics Phase 4
35 Cyclooxygenase Inhibitors Phase 4
36 Anti-Inflammatory Agents, Non-Steroidal Phase 4
37 Gastrointestinal Agents Phase 4
38 Antibodies, Monoclonal Phase 4
39 Tocolytic Agents Phase 4
40 Antibodies, Anti-Idiotypic Phase 4
41
Thalidomide Approved, Investigational, Withdrawn Phase 3 50-35-1 5426
42
Apremilast Approved, Investigational Phase 3 608141-41-9 11561674
43
Upadacitinib Approved, Investigational Phase 3 1310726-60-3 58557659
44
Ixekizumab Approved, Investigational Phase 3 1143503-69-8
45
tannic acid Approved Phase 3 1401-55-4
46
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
47
Ustekinumab Approved, Investigational Phase 3 815610-63-0
48 Chelating Agents Phase 3
49 Immunoglobulin Fab Fragments Phase 3
50 Sodium Pertechnetate Tc 99m Phase 3

Interventional clinical trials:

(show top 50) (show all 232)
# Name Status NCT ID Phase Drugs
1 TReat-to-tArget (T2T) With seCukinumab in Axial Spondyloarthritis. IdEntification of MRI and Biochemical Biomarkers for Disease Activity, Treatment Response and Structural Damage Progression (the TRACE Study) Unknown status NCT03639740 Phase 4 Secukinumab 150 milligram [Cosentyx]
2 Can New Imaging- and Bio-markers Improve the Assessment of Disease Activity and Progression and Predict Therapeutic Outcome in Spondyloarthritis Patients Receiving Adalimumab Unknown status NCT00477893 Phase 4 Adalimumab;Placebo
3 Risk of Tuberculosis and Infections in Spondyloarthritis Patients Treated With Tofacitinib in Bangladesh Unknown status NCT03504072 Phase 4 Tofacitinib 5 mg,;Etanercept
4 The Efficacy of Adalimumab and Conventional Antirheumatic Drugs in Alleviating Axial and Aortic Inflammation Detected in PET/CT in Patients With Axial Spondyloarthritis Unknown status NCT02634541 Phase 4 Adalimumab
5 Golimumab Versus Pamidronate for the Treatment of Axial Spondyloarthropathy: a 48-week Randomized Controlled Trial Completed NCT01718951 Phase 4 golimumab;Pamidronate
6 A Prospective Study of the Use of the Madrid Ultrasound Scoring System in the Treatment of Anti-TNF Blocker to Peripheral Tendonitis in Patients With Spondyloarthritis Completed NCT02960035 Phase 4 50mg etanercept;25mg etanercept;placebo
7 Effects of Nonsteroidal Anti-inflammatory Drug (NSAID) on Inflammatory Lesion of Axial Spondyloarthritis Results From MRI Finding Completed NCT03190603 Phase 4 Celecoxib
8 TNFalfa Blocking Treatment of Spondylarthropathies - A Danish Multicenter Study of New Methods for Better Monitoring and Prognostifying Patients With Spondylarthropathies Completed NCT00133315 Phase 4 Infliximab;Etanercept;Adalimumab
9 Evaluation of Clinical Value of Standardized Protocol for Dose-reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNF Therapy: Open-label, Controlled, Randomized, Multicenter Trial. Completed NCT01604629 Phase 4 Reduced doses of anti-TNF;Stable doses of anti-TNF
10 A Multicentre, Double-Blind, Placebo-Controlled, Randomized Study of Etanercept in the Treatment of Adults Patients With Refractory Heel Enthesitis in Spondylarthropathy Completed NCT00420303 Phase 4 Etanercept
11 Effects of Different Anti-rheumatic Treatments of Arthritis on Antibody Response Following Pneumococcal Vaccination Using Prevenar® Completed NCT00828997 Phase 4
12 Effect of Continuous Administration of Different Therapeutic Dosages of Indomethacin and Etoricoxib in the Management of Axial Spondyloarthritis: A Randomized Controlled Trial Completed NCT03582332 Phase 4 Indomethacin SR, 75 Mg Oral Capsule, Extended Release;Indomethacin 25 Mg Oral Capsule;Etoricoxib 90 mg;Etoricoxib 60 mg
13 Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease. Impact of Antirheumatic Treatment on Antibody Response. Completed NCT03762824 Phase 4
14 Treatment of Active Axial Spondyloarthritis by Recombinant Human Tumor Necrosis Factor-α Receptor â…¡ IgG Fc Fusion Protein Injection: a Randomized, Double-blind, Multicentral Clinical Trial to Investigate the Efficacy and Safety of Yisaipu® Completed NCT02364479 Phase 4 50mg Yisaipu;25mg etanercept;Placebo
15 Multicenter, Open-Label Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis Flares in Axial Spondyloarthritis Subjects With a History of Anterior Uveitis (C-VIEW) Completed NCT03020992 Phase 4 Certolizumab Pegol
16 Intestinal Inflammation in Ankylosing Spondylitis Assessed by Fecal Calprotectin, Capsular Endoscopy and Colonoscopy and the Effects of Adalimumab on Mucosal Healing Completed NCT01174186 Phase 4 Adalimumab
17 Adalimumab in Axial Spondyloarthritis. An Investigation of Whole-body MRI, MRI of Sacroiliac Joints and Spine and Soluble Biomarkers of Joint Inflammation and Damage. Completed NCT01029847 Phase 4 Adalimumab;Placebo
18 A Phase-IV, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of Golimumab (MK-8259 [SCH 900259]) After Treatment Withdrawal, Compared With Continued Treatment (Either Full- or Reduced-Treatment Regimen), In Subjects With Non-Radiographic Axial Spondyloarthritis Completed NCT03253796 Phase 4
19 A Multi Centre, Double Blind, Placebo-controlled Study to Evaluate the Non Steroidal Anti-inflamatory Drugs (NSAIDS) Sparing Effect of Etanercept in Adult Subjects With Axial Involvement of Spondyloarthritis Completed NCT01298531 Phase 4 etanercept;etanercept;placebo
20 Ultrasound Guided Epidural Block in Axial SPA Patient With Limited Spine Mobility: a Prospective Pilot Randomized Controlled Trial Completed NCT04143165 Phase 4 Epidural block with lidocaine and triamcinilone
21 A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SWITCHING FROM INNOVATOR INFLIXIMAB TO BIOSIMILAR INFLIXIMAB COMPARED WITH CONTINUED TREATMENT WITH INNOVATOR INFLIXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS, SPONDYLOARTHRITIS, PSORIATIC ARTHRITIS, ULCERATIVE COLITIS, CROHN'S DISEASE AND CHRONIC PLAQUE PSORIASIS THE NOR-SWITCH STUDY Completed NCT02148640 Phase 4 Innovator infliximab;Biosimilar infliximab
22 A Phase-IV, Multicenter, Noncomparative, Open-Label Study Evaluating the Safety and Efficacy of Golimumab (a Fully Human Anti-TNFα Monoclonal Antibody, Administered Subcutaneously) in the Treatment of Indian Patients With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis Recruiting NCT03733925 Phase 4 Golimumab
23 Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis Recruiting NCT03445845 Phase 4 Secukinumab;TNF blocker
24 Treat-to-target Strategy in Ankylosing Spondylitis Using Etanercept and Conventional Synthetic DMARDs, a Prospective Randomized Controlled Study Not yet recruiting NCT04077957 Phase 4 Methotrexate;Sulfasalazine;Hydroxychloroquine;Etanercept (50mg per week, for 4 weeks);Etanercept (50mg per week, for 2 weeks);Etanercept (50mg per week)
25 Study of Peripheral Enthesitis With Ultra Sonography Doppler in Spondyloarthropathies Treated With Infliximab Terminated NCT00686894 Phase 4 Infliximab
26 Discontinuation of TNF-alpha Inhibitors in Spondylarthritis Patients With Low Disease Activity, and Re-initiation of Therapy if Disease Flares Terminated NCT00726804 Phase 4 Discontinuation of TNF-alpha inhibitor and re-starting it if flare-up in disease activity (etanercept or adalimumab)
27 STRIKE - Treating Patients With Early Axial Spondyloarthritis to Target - a 1 Year Randomized Controlled Study Taking an Intense Treatment Approach Versus Routine Treatment Terminated NCT02897115 Phase 4
28 Comparative Analysis of Two Therapeutic Strategies: "Early Switch" Versus "Therapeutic Intensification" in Patients With Spondyloarthritis Treated With Anti-tnf Biologics, in Case of Secondary Treatment Failure Suspicion. Terminated NCT01971918 Phase 4
29 Non-Steroidal Anti-inflammatory Drugs in Axial Spondyloarthritis: a Pilot Study Terminated NCT03473665 Phase 4 Indomethacin;Diclofenac;Meloxicam;Celecoxib
30 Methotrexate in the Treatment of Axial Spondyloarthritis. A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study. Withdrawn NCT00298012 Phase 4 Methotrexate
31 Efficacy of Adalimumab (Humira®) in Spondyloarthritis Related to Crohn's Disease Withdrawn NCT00972218 Phase 4
32 Phase III Study of Human Bone Marrow-Derived Mesenchymal Stem Cells to Treat AS Unknown status NCT02809781 Phase 2, Phase 3 Etanercept
33 Safety and Efficacy of Tofacitinib in the Treatment of NSAID Refractory Axial Spondyloarthritis:A Clinical Trial Unknown status NCT03738956 Phase 2, Phase 3 Tofacitinib
34 Efficacy of Golimumab in Early Axial Spondyloarthritis in Relation to Gut Inflammation, an Early Remission Induction Study Unknown status NCT03270501 Phase 3 Golimumab
35 A Prospective Double Blind Placebo Controlled Trial of Combination Disease Modifying Antirheumatic Drugs (DMARDs) vs Monotherapy (Sulfasalazine) in Patients With Inflammatory Low Backache in Early Seronegative Spondylarthropathy Completed NCT01040195 Phase 3 Methotrexate, Hydroxychloroquine;Placebo
36 Efficacy, Safety, and Tolerability of Infliximab (Remicade; Schering-Plough) in Juvenile Spondyloarthropathies: a Three-Month, Randomized, Double-Blind, Placebo-Controlled Trial and 52-Week Open Extension. Completed NCT00591201 Phase 2, Phase 3 infliximab;Placebo
37 Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis Completed NCT01087762 Phase 3
38 Mechanism of Action Study of Anti-IL17 Treatment in Spondyloarthritis: Impact on Cellular and Molecular Pathways of Synovial Inflammation and Tissue Remodeling Completed NCT03358134 Phase 3 Secukinumab
39 Exploration of TNF-alpha Blockade With Golimumab in the Induction of Clinical Remission in Patients With Early Peripheral Spondyloarthritis (SpA) According to ASAS-criteria Completed NCT01426815 Phase 3 Placebo;Golimumab
40 A Multicenter, Randomized, Double-Blind, Study Comparing the Efficacy and Safety of Continuing Versus Withdrawing Adalimumab Therapy in Maintaining Remission in Subjects With Non-Radiographic Axial Spondyloarthritis Completed NCT01808118 Phase 3
41 A Multicentre, 12 Week Double Blind Placebo Controlled Randomized Study Of Etanercept On A Background Nsaid In The Treatment Of Adult Subjects With Non Radiographic Axial Spondyloarthritis With A 92 Week Open Label Extension Completed NCT01258738 Phase 3 Background NSAID;Background NSAID
42 A Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy in the Treatment of Enthesitis at the Achilles Tendon up to 1 Year in Adult Patients With Active Psoriatic Arthritis (PsA) and Axial Spondyloarthritis (axSpA) (ACHILLES) Completed NCT02771210 Phase 3 Secukinumab Placebo
43 A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study With an Open Label Extension to Evaluate the Efficacy and Safety of KHK4827 in Subjects With Axial Spondyloarthritis Completed NCT02985983 Phase 3 KHK4827;Placebo
44 A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Peripheral Spondyloarthritis Completed NCT01064856 Phase 3
45 A 24-week, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Secukinumab in Controlling Spinal Pain in Patients With Axial Spondyloarthritis Completed NCT03136861 Phase 3 AIN457 Placebo
46 A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis Completed NCT02757352 Phase 3 Ixekizumab;Placebo
47 A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Effect of Golimumab Administered Subcutaneously in Subjects With Active Axial Spondyloarthritis (Protocol No. P07642, Also Known as MK-8259-006-02). Completed NCT01453725 Phase 3
48 A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis Completed NCT02696798 Phase 3 Ixekizumab;Placebo
49 Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-Ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation Completed NCT02552212 Phase 3
50 Infliximab as First Line Therapy in Patients With Early Active Axial Spondyloarthritis Trial Completed NCT00844805 Phase 3 Infliximab;Placebo;Naproxen

Search NIH Clinical Center for Spondyloarthropathy

Cochrane evidence based reviews: spondylarthropathies

Sources

Genetic Tests for Spondyloarthropathy

About this section

Genetic tests related to Spondyloarthropathy:

# Genetic test Affiliating Genes
1 Spondyloarthropathy, Susceptibility to 29
Sources

Anatomical Context for Spondyloarthropathy

About this section

MalaCards organs/tissues related to Spondyloarthropathy:

40
Bone, Bone Marrow, Skin, T Cells, Eye, Spinal Cord, Skeletal Muscle
Sources

Publications for Spondyloarthropathy

About this section

Articles related to Spondyloarthropathy:

(show top 50) (show all 2019)
# Title Authors PMID Year
1
The usefulness and validity of English-language videos on YouTube as an educational resource for spondyloarthritis. 61
32880051 2021
2
Cytokine "fine tuning" of enthesis tissue homeostasis as a pointer to spondyloarthritis pathogenesis with a focus on relevant TNF and IL-17 targeted therapies. 61
33544244 2021
3
Characteristics, evolution, and outcome of patients with non-infectious uveitis referred for rheumatologic assessment and management: an Egyptian multicenter retrospective study. 61
32876781 2021
4
Value of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Spondyloarthropathy-Related Aortitis. 61
32028301 2021
5
Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials. 61
32910152 2021
6
Outcome of COVID-19 in hospitalized patients with chronic inflammatory diseases. A population based national register study in Denmark. 61
33812171 2021
7
Evaluation of a lateral flow assay-based IFN-γ release assay as a point-of-care test for the diagnosis of latent tuberculosis infection. 61
33666781 2021
8
Evaluation of the early cervical structural change in patients with non-radiographic axial spondyloarthropathy. 61
33675418 2021
9
The structural, functional and electrophysiological assessment of paraspinal musculature of patients with ankylosing spondylitis and non-radiographic axial spondyloarthropathy. 61
33502552 2021
10
Management and diagnosis of recurrent anterior uveitis due to underlying HLA-B27 positive, seronegative spondyloarthropathy. 61
32945004 2021
11
Haptoglobin and Its Related Protein, Zonulin-What Is Their Role in Spondyloarthropathy? 61
33800376 2021
12
Association Study between Psoriatic Arthritis and Killer Immunoglobulin-Like Receptor (KIR) Genes: A Meta-Analysis. 61
31957514 2021
13
Survey of Post-Cranial Skeletal Pathology in Snakes. 61
33714430 2021
14
Social isolation due to the COVID-19 pandemic has led to worse outcomes in females with inflammatory arthritis. 61
32656691 2021
15
Therapeutic exercises and rehabilitation in axial spondyloarthropathy: Balancing benefits with unique challenges in the Asia-Pacific countries. 61
33244895 2021
16
Frequency of pertinent MRI abnormalities of the sacroiliac joints of patients without spondyloarthropathies: a systematic review of the literature. 61
33547535 2021
17
COVID-19 and rheumatic musculoskeletal disease patients: infection rates, attitudes and medication adherence in an Irish population. 61
33164088 2021
18
Characterizing the alkaptonuria joint and spine phenotype and assessing the effect of homogentisic acid lowering therapy in a large cohort of 87 patients. 61
33452825 2021
19
Primary Total Hip Arthroplasty in Patients With Ankylosing Spondylitis. 61
33602587 2021
20
The Delay of Diagnosis in Spondyloarthropathy Patients in a Tertiary Hospital in Saudi Arabia. 61
33447495 2021
21
Assessment of plasma microRNA potentials as a non-invasive biomarker in patients with axial spondyloarthropathy. 61
33577015 2021
22
Real-world observational study of biosimilars in inflammatory arthritis treatment: a systematic literature review. 61
32808557 2021
23
Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. 61
32460374 2021
24
Unexpected increase of aortic stiffness in juvenile Spondyloarthropathies. 61
32938508 2020
25
Characterising the arthroplasty in spondyloarthropathy in a large cohort of eighty-seven patients with alkaptonuria. 61
33314212 2020
26
Interleukin-18, interleukin-20, and matrix metalloproteinases (MMP-1, MMP-3) as markers of psoriatic arthritis disease severity and their correlations with biomarkers of inflammation and turnover of joint cartilage. 61
33603622 2020
27
Pregnancy in axial spondyloarthropathy: A systematic review & meta-analysis. 61
33065422 2020
28
The Same But Different? An Analysis of Late-Onset Axial Spondyloarthropathy. 61
33394833 2020
29
Imaging of enthesitis by an LED-based photoacoustic system. 61
33331148 2020
30
Cervical Myelopathy Secondary to Gout: Case Report. 61
33364662 2020
31
Combined use of different antibody clones improves the efficiency of human leukocyte antigen B27 detection by flow cytometry. 61
33373171 2020
32
Coeliac disease is a risk factor for the development of seronegative arthritis in patients with autoimmune thyroid disease. 61
33197262 2020
33
Performance of the 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus in Asian patients: a single-centre retrospective cohort study in Korea. 61
32083550 2020
34
Long-term association between disease activity and disability in early axial spondyloarthritis: results from the DESIR cohort. 61
33207078 2020
35
Contemporary Primary Total Knee Arthroplasty is Durable in Patients Diagnosed With Ankylosing Spondylitis. 61
32653352 2020
36
Role of secukinumab in ankylosing spondylitis with tubercular uveitis. 61
33120695 2020
37
Do Smoking and Socioeconomic Factors Influence Imaging Outcomes in Axial Spondyloarthritis? Five-Year Data From the DESIR Cohort. 61
32562362 2020
38
Diagnostic efficacy of ultrasound detection of enthesitis in peripheral spondyloarthritis. 61
31663417 2020
39
Effectiveness of Ustekinumab on Crohn's Disease Associated Spondyloarthropathy: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). 61
32981373 2020
40
Performance of Janus kinase inhibitors in psoriatic arthritis with axial involvement in indirect comparison with ankylosing spondylitis: a retrospective analysis from pooled data. 61
33067773 2020
41
QuantiFERON®-TB Gold In-Tube test can be used for screening latent tuberculosis before biological treatment in a Bacille Calmette-Guérin (BCG)-vaccinated country: the HUR-BIO single-center real-life results. 61
33057917 2020
42
Intestinal and enthesis innate immunity in early axial spondyloarthropathy. 61
33053197 2020
43
Corrigendum to: Intestinal and enthesis innate immunity in early axial spondyloarthropathy. 61
33175969 2020
44
Peripheral Enthesitis in Spondyloarthritis: Lessons from Targeted Treatments. 61
32720292 2020
45
Patient-Centered Care in Psoriatic Arthritis-A Perspective on Inflammation, Disease Activity, and Psychosocial Factors. 61
32992983 2020
46
Evaluation of familial Mediterranean fever patients concomitant with juvenile spondyloarthropathy. 61
32815445 2020
47
Primary Hypoparathyroidism Mimicking Ankylosing Spondylitis in a Young Man with Fahr's Syndrome: A Case Report. 61
32944487 2020
48
Revision Total Hip Arthroplasty in Patients With Ankylosing Spondylitis: Long-Term Results. 61
32418748 2020
49
Surgical correction of rigid cervicothoracic deformity in a transgender patient: case report. 61
33102900 2020
50
Pharmacological treatment for managing bone health in axial spondyloarthropathy: systematic review and meta-analysis. 61
32556472 2020
Sources

Variations for Spondyloarthropathy

About this section
Sources

Expression for Spondyloarthropathy

About this section
Search GEO for disease gene expression data for Spondyloarthropathy.
Sources

Pathways for Spondyloarthropathy

About this section

Pathways related to Spondyloarthropathy according to GeneCards Suite gene sharing:

(show top 50) (show all 82)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 14.06 TNFSF11 TNF MMP3 LTA KIR3DL1 IL6
2
ERK Signaling 63
Show member pathways
 13.93 TNFSF11 TNF LTA IL6 IL4 IL23A
3
PEDF Induced Signaling 63
Show member pathways
 13.8 TNFSF11 TNF LTA IL6 IL4 IL23A
4
TGF-Beta Pathway 63
Show member pathways
 13.67 TNF LTA IL6 IL4 IL23A IL22RA1
5
Akt Signaling 63
Show member pathways
 13.54 TNFSF11 TNF LTA IL6 IL4 IL23A
6
PAK Pathway 63
Show member pathways
 13.42 TNFSF11 TNF LTA IL6 IL4 IL23A
7
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.28 TNF MMP3 IL6 IL2 IL1B IL10
8
PI3K-Akt signaling pathway 36
Show member pathways
 13.11 TNF IL6 IL4 IL2 HLA-C HLA-B
9
Human cytomegalovirus infection 36
Show member pathways
 13.02 TNF IL6 IL1B HLA-C HLA-B HLA-A
10
Measles 36
Show member pathways
 12.98 TNF IL6 IL2 IL1B IFNG HLA-C
11
Herpes simplex virus 1 infection 36
12.96 TNF LTA IL6 IL1B IFNG HLA-C
12
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 64
Show member pathways
 12.83 TNF LTA IL6 IL4 IL2
13
NF-KappaB Family Pathway 63
Show member pathways
 12.77 TNF LTA IL6 IL2 IL1B
14
T cell receptor signaling pathway 36
Show member pathways
 12.75 TNF IL6 IL4 IL2 IL1B IL17A
15
Immune response IL-23 signaling pathway 23
Show member pathways
 12.72 TNF IL6 IL23A IL2 IL1B IL17F
16
Immune response NFAT in immune response 23
Show member pathways
 12.71 TNF IL4 IL2 IL10 IFNG
17
NF-kappaB Signaling 4
12.71 TNFSF11 TNF IL4 IL2 IL1B IL17A
18
Th17 cell differentiation 36
Show member pathways
 12.68 TNF IL6 IL4 IL23A IL22RA1 IL2
19
Immune response Role of DAP12 receptors in NK cells 23
Show member pathways
 12.66 TNF KIR3DL1 IL4 IL2 IFNG HLA-C
20
Cytokine Signaling in Immune system 65
Show member pathways
 12.66 TNFSF11 TNF MMP3 LTA IL6 IL4
21
JAK-STAT signaling pathway 36
Show member pathways
 12.59 IL6 IL4 IL23A IL22RA1 IL2 IL10
22
Allograft rejection 1 36
Show member pathways
 12.51 TNF LTA KIR3DL1 IL6 IL4 IL2
23
Human T-cell leukemia virus 1 infection 36
12.5 TNF LTA IL6 IL2 HLA-C HLA-B
24
Chemokine Superfamily Pathway: Human/Mouse Ligand-Receptor Interactions 64
Show member pathways
 12.49 TNF LTA IL6 IL22RA1 IL2 IL10
25
Folate Metabolism 1
Show member pathways
 12.49 TNF IL6 IL4 IL2 IL1B IFNG
26
IL-17 Family Signaling Pathways 64
Show member pathways
 12.48 TNF MMP3 IL6 IL4 IL1B IL17F
27
Tuberculosis 36
12.41 TNF IL6 IL23A IL1B IL10 IFNG
28
Toxoplasmosis 36
Show member pathways
 12.39 TNF IL4 IL1B IL10 IFNG
29
C-type lectin receptor signaling pathway 36
Show member pathways
 12.38 TNF IL6 IL23A IL2 IL1B IL10
30
Bacterial infections in CF airways 23
Show member pathways
 12.33 TNF IL6 IL4 IL1B IFNG
31
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.26 TNF IL6 IL1B IL10
32
Cellular senescence (KEGG) 36
12.24 IL6 HLA-C HLA-B HLA-A
33
Yersinia infection 36
12.24 TNF IL6 IL2 IL1B IL10
34
Spinal Cord Injury 1
12.19 TNF IL6 IL4 IL2 IL1B IFNG
35
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell 65
12.17 KIR3DL1 HLA-C HLA-B HLA-A
36
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 64
12.17 TNF IL6 IL4 IL2 IL10 IFNG
37
Osteoclast differentiation 36
12.15 TNFSF11 TNF IL1B IFNG
38
IL12-mediated signaling events 1
Show member pathways
 12.15 IL4 IL2 IL1B IFNG HLA-A
39
TNF signaling pathway 36
12.14 TNF MMP3 LTA IL6 IL1B
40
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 12.14 TNF LTA IL6 IL4 IL2 IL1B
41
Amoebiasis 36
12.09 TNF IL6 IL1B IL10 IFNG
42
NF-kappa B signaling pathway 36
12.05 TNFSF11 TNF LTA IL1B
43
Rheumatoid arthritis 36
12.05 TNFSF11 TNF MMP3 IL6 IL23A IL1B
44
Hematopoietic cell lineage 36
12.03 TNF IL6 IL4 IL1B
45
Th17 Differentiation Pathway 64
Show member pathways
 12.03 IL6 IL4 IL23A IL1B IL17F IL17A
46
Interleukin-4 and 13 signaling 65
12.03 TNF MMP3 IL6 IL4 IL23A IL1B
47
Cytokine production by Th17 cells in CF (Mouse model) 23
Show member pathways
 12 IL6 IL23A IL17F IL17A
48
Pertussis 36
11.95 TNF IL6 IL23A IL1B IL10
49
Glucocorticoid receptor regulatory network 1
11.94 IL6 IL4 IL2 IFNG
50
Th1 Differentiation Pathway 64
Show member pathways
 11.94 TNF LTA IL6 IL2 IL1B IL17A
Sources

GO Terms for Spondyloarthropathy

About this section

Cellular components related to Spondyloarthropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.77 TNFSF11 TNF MMP3 LTA IL6 IL4
2 phagocytic vesicle membrane GO:0030670 9.54 HLA-C HLA-B HLA-A
3 ER to Golgi transport vesicle membrane GO:0012507 9.5 HLA-C HLA-B HLA-A
4 extracellular space GO:0005615 9.44 TNFSF11 TNF MMP3 LTA IL6 IL4
5 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.43 HLA-C HLA-B HLA-A
6 MHC class I protein complex GO:0042612 9.33 HLA-C HLA-B HLA-A

Biological processes related to Spondyloarthropathy according to GeneCards Suite gene sharing:

(show top 50) (show all 83)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.24 TNFSF11 TNF IL6 IL4 IL23A IL2
2 immune system process GO:0002376 10.22 IL23A IL2 IL17F IL17A HLA-C HLA-B
3 innate immune response GO:0045087 10.18 IL23A IL17F IL17A HLA-C HLA-B HLA-A
4 positive regulation of gene expression GO:0010628 10.16 TNFSF11 TNF IL6 IL4 IL1B IFNG
5 inflammatory response GO:0006954 10.12 TNF IL6 IL23A IL1B IL17F IL17A
6 adaptive immune response GO:0002250 10.11 IL2 IL17F IL17A IFNG HLA-C HLA-B
7 cell-cell signaling GO:0007267 10.06 LTA IL2 IL1B IL17A
8 regulation of immune response GO:0050776 10.05 KIR3DL1 IL4 HLA-C HLA-B HLA-A
9 positive regulation of protein phosphorylation GO:0001934 10.04 TNF IL2 IL1B IFNG
10 cellular response to lipopolysaccharide GO:0071222 10.03 TNF IL6 IL1B IL10
11 positive regulation of NF-kappaB transcription factor activity GO:0051092 10.02 TNFSF11 TNF IL6 IL1B
12 positive regulation of tumor necrosis factor production GO:0032760 9.96 IL6 IL23A IL17A IFNG
13 positive regulation of DNA-binding transcription factor activity GO:0051091 9.95 TNFSF11 TNF IL6 IL1B IL10
14 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0002479 9.93 HLA-C HLA-B HLA-A
15 regulation of insulin secretion GO:0050796 9.93 TNF IL6 IL1B IFNG
16 interferon-gamma-mediated signaling pathway GO:0060333 9.93 IFNG HLA-C HLA-B HLA-A
17 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.92 TNF IL23A IL1B
18 type I interferon signaling pathway GO:0060337 9.92 HLA-C HLA-B HLA-A
19 response to glucocorticoid GO:0051384 9.92 TNF IL6 IL10
20 positive regulation of interleukin-8 production GO:0032757 9.92 TNF IL6 IL1B
21 positive regulation of protein complex assembly GO:0031334 9.92 TNF MMP3 IFNG
22 positive regulation of inflammatory response GO:0050729 9.92 TNF IL23A IL2 IL1B IFNG
23 positive regulation of cytokine production GO:0001819 9.91 TNF IL10 IFNG
24 humoral immune response GO:0006959 9.91 TNF LTA IL6 IFNG
25 defense response to Gram-negative bacterium GO:0050829 9.91 IL6 IL23A IL22RA1 IL17F IL17A
26 positive regulation of interleukin-1 beta production GO:0032731 9.9 TNF IL6 IL17A IFNG
27 positive regulation of phagocytosis GO:0050766 9.89 TNF IL1B IFNG
28 antigen processing and presentation GO:0019882 9.89 HLA-C HLA-B HLA-A
29 positive regulation of nitric oxide biosynthetic process GO:0045429 9.89 TNF IL1B IFNG
30 positive regulation of interleukin-12 production GO:0032735 9.88 IL23A IL17A IFNG
31 positive regulation of chemokine production GO:0032722 9.88 TNF IL6 IFNG
32 defense response to Gram-positive bacterium GO:0050830 9.88 TNF LTA IL6 IL17F IL17A HLA-A
33 positive regulation of interleukin-10 production GO:0032733 9.87 IL6 IL4 IL23A
34 positive regulation of JAK-STAT cascade GO:0046427 9.87 TNF IL6 IL10
35 microglial cell activation GO:0001774 9.86 TNF IL4 IFNG
36 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.86 HLA-C HLA-B HLA-A
37 positive regulation of T cell proliferation GO:0042102 9.85 IL6 IL4 IL23A IL2 IL1B
38 positive regulation of interleukin-6 production GO:0032755 9.85 TNF IL6 IL1B IL17F IL17A IFNG
39 negative regulation of neurogenesis GO:0050768 9.84 TNF IL6 IL1B
40 positive regulation of T cell mediated cytotoxicity GO:0001916 9.83 IL23A HLA-B HLA-A
41 positive regulation of immunoglobulin production GO:0002639 9.82 IL6 IL2 IL10
42 positive regulation of interleukin-17 production GO:0032740 9.81 IL6 IL23A IL2
43 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.8 TNF IL1B IFNG
44 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.8 TNF IL6 IL17F IL17A
45 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.8 TNF IL6 IL4 IL23A IL2 IFNG
46 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.79 TNF IL1B IL10
47 positive regulation of neuroinflammatory response GO:0150078 9.79 TNF IL6 IL1B
48 positive regulation of MHC class II biosynthetic process GO:0045348 9.77 IL4 IL10 IFNG
49 negative regulation of amyloid-beta clearance GO:1900222 9.76 TNF IFNG
50 regulation of neuroinflammatory response GO:0150077 9.76 MMP3 IL6

Molecular functions related to Spondyloarthropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.62 IL6 IL4 IL2 IL10
2 peptide antigen binding GO:0042605 9.43 HLA-C HLA-B HLA-A
3 cytokine activity GO:0005125 9.4 TNFSF11 TNF LTA IL6 IL4 IL23A
4 tumor necrosis factor receptor binding GO:0005164 9.33 TNFSF11 TNF LTA
5 TAP binding GO:0046977 9.13 HLA-C HLA-B HLA-A
Sources

Sources for Spondyloarthropathy

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....